Company Name: ZS Pharma Inc.
Location: Ft. Worth, Texas
Automation Didn’t Dehumanize Care. Bad Systems Did.
We have the opportunity to design systems that give people greater capacity for the work where human presence matters most: listening, understanding, reassuring, deciding, and caring.
Industry: Pharmaceuticals
Solution/Product: ZS-9, an oral sorbent technology platform that will first be applied to removing toxins in patients suffering from hyperkalemia, or high levels of potassium in the blood, as a result of kidney and liver disease and related conditions.
Money Raised: $5.3 million since November
How will it be used: First round of clinical trials to test the drug in acute hyperkalemia, according to the Dallas Business Journal. President and CEO Al Guillem wasn’t immediately available to comment.
The Healthcare Payments Industry Faces a Perception Challenge
Healthcare payments are no longer about transactions. It’s about controlling the revenue cycle. And increasingly, that control is not sitting with ISOs.
Investors: The filing lists Marc Ostro, of Devon Park Bioventures, and Robert Truitt, of Ash Access Technology, among the company’s board of directors. In 2010, ZS Pharma received $2 million from the state’s Emerging Technology Fund.
Competitors: Artificial kidneys like the ones being developed by researchers at UCSF, CreatiVasc Medical; Blood Purification Technologies.